Hep C is a devastating disease, frequently leading to liver cancer and a certain and painful end. Sadly, I watched this process first hand several years ago as my mother slowly succumbed after a year of futile painful treatments. I truly hope that MACK will be an important part of the cure. A note of caution, Hep C has extracted a financial price on shareholders of Bristol Myers/Inhibitex, $1.8 billion write off, Vertex, and Idenix all capable companies with promising innovative new solutions to re-mediating Hep C......all failures. Let's cheer for MACK, but temper our investment expectations with the difficult and uncertain nature of their task and the sober reality that MACK needs a cash infusion from either partnerships or issuing new dilutive shares. MACK already has 78.1newly tradable shares this week in addition to the 14.3 issued in the IPO. The shares could test the Sept 17. $ 8.03 low.